Bound­less starts IPO spring with $100M list­ing for can­cer small mol­e­cules

$BOLD will take flight on Thurs­day morn­ing.

Bound­less Bio, a San Diego can­cer biotech, will raise about $100 mil­lion in its ini­tial pub­lic of­fer­ing by pric­ing at $16 apiece, the mid-point of the range it pro­posed last week. 

The clin­i­cal-stage start­up will sell 6.25 mil­lion shares, the amount it orig­i­nal­ly set out to of­fer, it said in a Wednes­day evening press re­lease.

The Nas­daq de­but will pad Bound­less’ run­way as it con­ducts two ear­ly-stage clin­i­cal tri­als of its oral small mol­e­cules. It had about $120 mil­lion in cash, equiv­a­lents and short-term in­vest­ments head­ed in­to 2024.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER